TG Therapeutics Reports Positive Phase 1 Data for Subcutaneous BRIUMVI, Supporting Quarterly Dosing and Potential Market Expansion
TGTX sits 45% above its 52-week low of $25.28.
Summary
TG Therapeutics reported positive Phase 1 data for a subcutaneous formulation of BRIUMVI, indicating strong potential for a self-administered, at-home quarterly treatment that could significantly expand its market.
Key Events · Product Development and Regulatory · TGTX
-
Positive Phase 1 Results for Subcutaneous BRIUMVI
TG Therapeutics announced positive pharmacokinetic (PK), pharmacodynamic (PD), safety, and tolerability data from its Phase 1 clinical trial evaluating a subcutaneous formulation of ublituximab (BRIUMVI®).
-
Supports Phase 3 Quarterly Dosing Regimen
The Phase 1 data strengthens confidence that the quarterly subcutaneous dosing regimen, currently being evaluated in a fully enrolled Phase 3 study, can achieve its primary endpoint of non-inferior drug exposure.
-
Potential for Market Expansion
The CEO stated that a self-administered, at-home, quarterly anti-CD20 therapy could nearly double the addressable market opportunity for the BRIUMVI franchise.
-
No New Safety Signals Observed
The novel high-concentration subcutaneous formulation was well-tolerated, with treatment-emergent adverse events consistent with the known safety profile of IV BRIUMVI and no new safety signals.
Analysis · TGTX · Life Sciences
TG Therapeutics announced positive Phase 1 clinical trial results for a subcutaneous formulation of BRIUMVI, its approved multiple sclerosis drug. This data is crucial as it supports the ongoing Phase 3 trial for a more convenient, self-administered, at-home quarterly dosing regimen. The company's CEO highlighted that a subcutaneous option could nearly double the addressable market for the BRIUMVI franchise, representing a significant commercial opportunity. The positive safety and pharmacokinetic/pharmacodynamic data de-risks the Phase 3 program, with topline results expected in late 2026 or early 2027.
At the time of this filing, TGTX was trading at $36.65 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.6B. The 52-week trading range was $25.28 to $44.65. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.